Teladoc Health executive Bliss Kelly exercised Options covering 15,311 shares across three transactions on September 1, 2026. The transactions leave investors with updated ownership records showing 92,832 Teladoc shares after a subsequent sale and 7,798 derivative securities held by Kelly.
Key Highlights
- Bliss Kelly sold 7,357 Teladoc Health shares at $6.30 per share on September 2, 2026.
- Kelly’s reported ownership stood at 92,832 Teladoc Health shares after the sale.
- Kelly held 7,798 derivative securities after the option exercises.
Bliss Kelly, Teladoc Health, Inc. (NYSE: TDOC)’s President, U.S. Group Health, exercised options covering 15,311 shares across three transactions on September 1, 2026. The transactions were recorded at $0 per share and were followed by a sale of Teladoc shares the next day.
Kelly’s Share Transactions
Kelly, Teladoc Health’s President, U.S. Group Health, reported ownership of 100,189 shares after the option exercises. On September 2, 2026, Kelly sold 7,357 shares at $6.30 per share. The reported share balance after that sale was 92,832. The option exercises covered 15,311 shares in total across three separate transactions. The exercise price was $0 per share.
Derivative Securities Holdings
Those derivative securities were exercised at $0 per share. Kelly’s reported holdings after the transactions included 7,798 derivative securities.
FAQs
Q: What did Bliss Kelly do with Teladoc Health shares?
A: Bliss Kelly exercised options covering 15,311 Teladoc Health shares across three transactions on September 1, 2026, then sold 7,357 shares at $6.30 each.
Q: How many Teladoc Health shares does Bliss Kelly own after the sale?
A: Teladoc Health’s ownership record showed Bliss Kelly with 92,832 shares after the September 2, 2026, sale of 7,357 shares. The filing stated this was her ownership after that transaction.
Q: How many derivative securities does Bliss Kelly hold?
A: Following the option transactions, Bliss Kelly held 7,798 derivative securities of Teladoc Health. The exercises covered 15,311 derivative securities at $0 per share.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.